RBCC Continues Negotiations With Amarantus

RBCC Continues Negotiations With Amarantus

<0> Rainbow Coral Corp.Patrick Brown, 813-367-9511President and CEO </0>

Rainbow BioSciences, the biotechnology subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), continues its negotiations toward a definitive agreement with emerging biotech innovator Amarantus BioSciences (OTCBB: AMBS).

RBCC is in talks to provide funding and expertise toward the development and marketing of one or more of Amarantus’ exciting medical breakthroughs. The company is developing thrilling new ways to effectively diagnose and treat devastating neurological disorders including Parkinson’s disease and Traumatic Brain Injury (TBI).

Amarantus owns the rights to a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis as well as the license to a groundbreaking diagnostic platform called NuroPro that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients.

“The breakthroughs that Amarantus is currently working on don’t exist in the marketplace today,” said RBCC CEO Patrick Brown. “Their therapeutic potential is enormously exciting, and we have high hopes for both their disease-fighting abilities as well as their immediate commercial appeal.”

Rainbow BioSciences is working to develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB) and Elan Corp. (NYSE: ELN).

For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at []. For investment information and performance data on the company, please visit .

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.